Neffy Epinephrine Nasal Spray Approved in Canada as First Needle-Free Anaphylaxis Treatment by ARS Pharmaceuticals

Key Takeaways

• Health Canada approves neffy® as the first and only needle-free epinephrine treatment for severe allergic reactions and anaphylaxis
• The nasal spray offers a breakthrough alternative to traditional auto-injectors for adults and children weighing over 30kg
• ALK-Abelló will market neffy in Canada with expected availability in summer 2026

---

Revolutionary Needle-Free Treatment Gets Regulatory Green Light

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) announced that Health Canada has approved neffy® (epinephrine nasal spray), marking a significant milestone as the country’s first needle-free emergency treatment for severe allergic reactions and anaphylaxis. The approval covers use in adults and children weighing more than 30 kilograms.

Market Impact and Licensing Partnership

ALK-Abelló A/S holds the exclusive rights to market neffy in Canada and expects the treatment to become available to patients by summer 2026. This approval represents a major advancement for the estimated millions of Canadians living with severe food allergies and at risk of anaphylaxis.

Addressing Critical Treatment Barriers

Traditional epinephrine auto-injectors, while life-saving, present significant barriers including needle phobia, injection anxiety, and potential administration errors during emergency situations. Neffy’s intranasal delivery system eliminates these concerns while maintaining the critical speed required for anaphylaxis treatment.

Clinical Significance and Patient Benefits

The nasal spray formulation offers several advantages over conventional treatments:

• Ease of administration: No injection training required for patients or caregivers
• Reduced anxiety: Eliminates needle-related fears that may delay treatment
• Improved compliance: More likely to be carried and used when needed
• Emergency accessibility: Can be administered by bystanders without medical training

Company Background and Mission

ARS Pharmaceuticals focuses on developing innovative treatments for patients at risk of severe allergic reactions. The company’s dedication to empowering at-risk patients and their caregivers aligns with the critical need for more accessible emergency anaphylaxis treatments.

This Canadian approval follows regulatory successes in other markets and positions neffy as a game-changing option for emergency allergy management across North America.

---

Frequently Asked Questions

What does this approval mean for patients with severe allergies?

Patients now have access to the first needle-free epinephrine treatment option, which eliminates injection anxiety and makes emergency treatment more accessible for those who may avoid carrying traditional auto-injectors due to needle phobia.

When will neffy be available in Canadian pharmacies?

ALK-Abelló expects neffy to become available in Canada by summer 2026, giving patients and healthcare providers time to prepare for this new treatment option.

How does neffy compare to traditional epinephrine auto-injectors?

Neffy delivers the same life-saving epinephrine medication but through nasal spray instead of injection, eliminating needles while maintaining the rapid onset needed for anaphylaxis treatment. It’s approved for the same patient population - adults and children over 30kg.